MAP4K1 INHIBITORS

1 - 30 . (canceled)

31 . A method for treating a cancer or a viral infection, in a subject in need thereof, comprising administering to said subject an effective amount of the compound of Formula I:

or a pharmaceutically acceptable salt thereof,

wherein:

T is selected from

 and 4-5 membered heterocycle containing

 wherein said heterocycle of T is optionally substituted with 1-2 R 6 ;

Z is absent, O or NH;

Ring A is C 4-6 cycloalkyl or 4-6 membered heterocycle containing nitrogen, wherein said cycloalkyl or heterocycle of Ring A is optionally substituted with 1-2 R 6 ;

L 1 is selected from bond and C 1 -C 3 alkylene, wherein said alkylene of L 1 is optionally substituted with 1-2 R 1 ;

L 2 is selected from bond and C 1 -C 3 alkylene;

B is O or NH;

Q is N or CH:

x is 0, 1, or 2;

n is 0, 1, 2, 3, or 4;

R 1 and R 2 are each independently selected from hydrogen, C 1-6 alkyl, C 3-6 cycloalkyl, and 4 to 6-membered heterocycle, wherein said alkyl of R 1 and R 2 is optionally substituted with 1-2 R 3 ;

each R 3 is independently selected from halogen, hydroxyl and OR 4 ;

each R 4 is independently selected from C 1-3 alkyl, CF 3 , CH 2 F, and CHF 2 ;

each R 5 is independently selected from C 1-2 alkyl, CF 3 , CH 2 F, and CHF 2 , or

two R 5 attached to the same carbon atom taken together with the carbon atom to which they attach form C 3-5 cycloalkyl; or two R 5 attached to two adjacent carbon atoms taken together with the two adjacent carbon atoms to which they attach form C 4-6 cycloalkyl;

each R 6 is independently selected from CH 3 , methoxy, CF 3 , CH 2 F, and CHF 2 ;

R 7 is selected from C 1-3 alkyl, C 3-6 cycloalkyl, OC 1-4 alkyl, NR 9 R 10 , and 3-5 membered heterocycle containing nitrogen or oxygen, wherein said alkyl, cycloalkyl, or heterocycle of R 7 is optionally substituted with 1-3 R 8 ;

each R 8 is independently selected from halogen, C 1-3 alkyl, hydroxyl and OC 1-3 alkyl, wherein said alkyl of R 8 is optionally substituted with 1-3 R 12 ;

R 9 is selected from C 1-2 alkyl;

R 10 is selected from C 1-2 alkyl;

each R 11 is independently selected from halogen, methoxy, C 1-2 alkyl, CH 2 F, CHF 2 and CF 3 , or two R 11 taken together with the two adjacent carbon atoms to which they attach form cyclopropyl; and

each R 12 is halogen.

32 . The method of claim 31 , wherein said MAP4K1-dependent disease or disorder is a cancer.

33 . The method of claim 32 , wherein the cancer comprises at least one cancer selected from the group consisting of colon cancer, rectal cancer, pancreatic cancer, breast cancer, prostate cancer, lung cancer, ovarian cancer, cervical cancer, renal cancer, urothelial cancer, bladder cancer, esophageal cancer, stomach cancer, liver cancer, cancer of the head and neck, lymphoma, leukemia, and melanoma.

34 . The method of claim 32 , wherein said method further comprises administering an additional anti-cancer agent to said subject.

35 . The method of claim 31 , wherein the MAP4K1-dependent disorder or disease is a viral infection.

36 - 38 . (canceled)

39 . The method of claim 31 , wherein the compound is represented by Formula IV:

or a pharmaceutically acceptable salt thereof.

40 . The method of claim 31 , wherein the compound is represented by Formula VII:

or a pharmaceutically acceptable salt thereof.

41 . The method of claim 39 , wherein:

L 1 is bond;

T is

 and

L 2 is a bond or methylene.

42 . The method of claim 41 , wherein Ring A is selected from azetidinylene, cyclobutylene, cyclopentylene and pyrrolidinylene, wherein said azetidinylene, cyclobutylene, cyclopentylene and pyrrolidinylene is optionally substituted with 1-2 R 6 .

43 . The method of claim 39 , wherein:

L 1 is C 1 -C 3 alkylene optionally substituted with 1-2 R 11 ; and

T is

44 . The method of claim 43 , wherein L 1 is selected from Formula L-1, L-2, L-3, L-4, L-5, L-6 and L-7:

wherein:

represents a bond to B; and

-* represents a bond to T.

45 . The method of claim 44 , wherein Z is O.

46 . The method of claim 39 , wherein:

T is 4-5 membered heterocycle containing sulfone, wherein said heterocycle is optionally substituted with 1-2 R 6 ; and

L 1 is selected from bond, methylene and ethylene.

47 . The method of claim 45 , wherein:

R 1 and R 2 are each independently selected from hydrogen, C 1-6 alkyl, and C 3-6 cycloalkyl, wherein said alkyl is optionally substituted with R 3 ;

each R 3 is independently selected from halogen, hydroxyl and OR 4 ; and

each R 4 is C 1-3 alkyl.

48 . The method of claim 47 , wherein R 1 and R 2 are each independently selected from hydrogen, CH 3 , CH 2 CH 3 , CH 2 CH 2 CH 3 , CH 2 —OCH 3 and cyclopropyl.

49 . The method of claim 48 , wherein:

R 5 is CH 3 , or two R 5 attached to the same carbon atom taken together with the carbon atom to which they attach form cyclopropyl;

n is 1, 2, 3 or 4;

R 7 is selected from C 1-3 alkyl, CH 2 F, CHF 2 , CF 3 , C 3-6 cycloalkyl and NR 9 R 10 ;

R 9 is selected from C 1-2 alkyl; and

R 10 is selected from C 1-2 alkyl.

50 . The method of claim 49 , wherein R 7 is selected from CH 3 , CF 3 , CH 2 CH 3 , CH(CH 3 ) 2 , cyclopropyl and N(CH 3 ) 2 ; and each R 11 is independently CH 3 , CF 3 or CH 2 CH 3 .

51 . The method of claim 50 , wherein each R 11 is CH 3 .

52 . The method of claim 31 , wherein the compound is selected from

or a pharmaceutically acceptable salt thereof.